PHARMACOTHERAPEUTIC CHALLENGES OF VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN RETINAL VEIN OCCLUSION

Marianne Levon Shahsuvaryan*

MD, PhD, Dr of Sc., Professor, Department of Ophthalmology, Yerevan State Medical University, Yerevan, Armenia.

Corresponding Author: Marianne Levon Shahsuvaryan, MD, PhD, Dr of Sc., Professor, Department of Ophthalmology, Yerevan State Medical University, Yerevan, Armenia, Email mar_shah@hotmail.com, ORCID 0000-0003-3627-4137.

Citation: Marianne Levon Shahsuvaryan (2026). Pharmacotherapeutic Challenges of Vascular Endothelial Growth Factor Inhibitors in Retinal Vein occlusion Eco Science Journal.2026 3 (2).

Copyrights ©  2026, Marianne Levon Shahsuvaryan. This article is licensed under the Creative Common Attribution-NonCommercial-4.0-international-License-(CCBY-NC).

Abstract: Currently intravitreal antiangiogenics are undoubtedly efficacious in retinal vein occlusion (RVO), however prevailing safety concerns continue to be a key reason for continued high-quality clinical studies in the real world, taken into account that the patients with comorbidities are excluded from the randomized controlled trials. Recent studies substantiate the relevance of optimizing pharmacotherapy of RVO. Hopefully a noninvasive, multitarget, affordable, time- and cost-saving pharmacotherapy of RVO may offer a more efficient alternative to antiangiogenics monotherapy in the foreseeable future.                                      

Keywords:  Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor Inhibitors, Therapeutic Uses, Ophthalmopharmacotherapy, Injections, Intraocular; Retinal Vein Occlusion.